ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
CHINA BULLETIN: PMI Readings Signal Strong End to 2023
In this week’s issue New Year’s travel bounces back, Wanda sells off shopping malls and a top influencer topples a CEO. On a scale of 1 to 100, we give…
Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
